Monthly money

Versartis Inc. expects last week's $25 million series C round will get it to a Phase Ib/IIa data event for a long-acting recombinant human growth hormone to treat growth hormone deficiency. The product's once-monthly dosing would trump both the marketed daily version of hGH and the handful of once-weekly versions in the clinic.